Listed

C4 Therapeutics, Inc.

CCCCNasdaqCIK 1662579HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$6.6mRevenue, Q2 FY2026, three months to 2026-06-30$6.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001628280-26-055494.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 11, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$6.6mRevenue, Q2 FY2026, three months to 2026-06-30$6.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001628280-26-055494.Report this figure+2.8% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin−397.9%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$26.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001628280-26-055494.Revenue: $6.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001628280-26-055494.Report this figure+43.1 pts on a year earlier
  • Net margin−355.9%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$23.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001628280-26-055494.Revenue: $6.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001628280-26-055494.Report this figure+46.7 pts on a year earlier
  • Diluted EPS−$0.18Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.18 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001628280-26-055494.Report this figure+51.4% on a year earlier
  • Free cash flow−$1.6mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$1.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001628280-26-055494. Derived: 6-month figure less the 3-month figure.Capital expenditure: $37.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-11, accession 0001628280-26-055494. Derived: 6-month figure less the 3-month figure.Report this figure+86.8% on a year earlier

Last eight quarters

Full statements
Revenue$6.6mOperating margin −397.9%
Diluted EPS−$0.18, Q2 FY2026
Free cash flow−$1.6m, Q2 FY2026
C4 Therapeutics, Inc., key figures for the last eight quarters
Line itemUnitQ1 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m15.4Revenue, Q1 FY2024, three months to 2024-09-30$15.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001628280-25-049854.Report this figure5.2Revenue, Q4 FY2024, three months to 2024-12-31$5.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012000. Derived: 12-month figure less the 9-month figure.Report this figure7.2Revenue, Q1 FY2025, three months to 2025-03-31$7.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001628280-26-033865.Report this figure6.5Revenue, Q2 FY2025, three months to 2025-06-30$6.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001628280-26-055494.Report this figure11.2Revenue, Q3 FY2025, three months to 2025-09-30$11.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001628280-25-049854.Report this figure11.0Revenue, Q4 FY2025, three months to 2025-12-31$11.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012000. Derived: 12-month figure less the 9-month figure.Report this figure6.2Revenue, Q1 FY2026, three months to 2026-03-31$6.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001628280-26-033865.Report this figure6.6Revenue, Q2 FY2026, three months to 2026-06-30$6.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001628280-26-055494.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(183.9%)Operating margin, Q1 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$28.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001628280-25-049854.Revenue: $15.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001628280-25-049854.Report this figure(728.4%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$37.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012000. Derived: 12-month figure less the 9-month figure.Revenue: $5.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012000. Derived: 12-month figure less the 9-month figure.Report this figure(402.9%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$29.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-12, accession 0001628280-26-033865.Revenue: $7.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001628280-26-033865.Report this figure(441.0%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$28.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001628280-26-055494.Revenue: $6.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001628280-26-055494.Report this figure(306.4%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$34.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001628280-25-049854.Revenue: $11.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001628280-25-049854.Report this figure(210.1%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$23.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012000. Derived: 12-month figure less the 9-month figure.Revenue: $11.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012000. Derived: 12-month figure less the 9-month figure.Report this figure(451.6%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$27.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-12, accession 0001628280-26-033865.Revenue: $6.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001628280-26-033865.Report this figure(397.9%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$26.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001628280-26-055494.Revenue: $6.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001628280-26-055494.Report this figure
Net margin%(160.6%)Net margin, Q1 FY2024, three months to 2024-09-30. net income / revenueNet income: −$24.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001628280-25-049854.Revenue: $15.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001628280-25-049854.Report this figure(667.8%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$34.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012000. Derived: 12-month figure less the 9-month figure.Revenue: $5.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012000. Derived: 12-month figure less the 9-month figure.Report this figure(363.7%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$26.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001628280-26-055494.Revenue: $7.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001628280-26-033865.Report this figure(402.6%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$26.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001628280-26-055494.Revenue: $6.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001628280-26-055494.Report this figure(286.4%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$32.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001628280-25-049854.Revenue: $11.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001628280-25-049854.Report this figure(186.0%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$20.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012000. Derived: 12-month figure less the 9-month figure.Revenue: $11.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012000. Derived: 12-month figure less the 9-month figure.Report this figure(408.5%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$25.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001628280-26-055494.Revenue: $6.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001628280-26-033865.Report this figure(355.9%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$23.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001628280-26-055494.Revenue: $6.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001628280-26-055494.Report this figure
Diluted EPS$ per share(0.35)Diluted EPS, Q1 FY2024, three months to 2024-09-30−$0.35 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001628280-25-049854.Report this figurenot reported (Diluted EPS not reported)(0.37)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.37 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001628280-26-033865.Report this figure(0.37)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.37 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001628280-26-055494.Report this figure(0.44)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001628280-25-049854.Report this figurenot reported (Diluted EPS not reported)(0.20)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001628280-26-033865.Report this figure(0.18)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.18 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001628280-26-055494.Report this figure
Free cash flow$m(24.1)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$24.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001628280-25-049854. Derived: 9-month figure less the 6-month figure.Capital expenditure: −$13.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001628280-25-049854. Derived: 9-month figure less the 6-month figure.Report this figure(17.9)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$17.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012000. Derived: 12-month figure less the 9-month figure.Capital expenditure: −$4.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-012000. Derived: 12-month figure less the 9-month figure.Report this figure(33.3)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$33.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001628280-26-033865.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-12, accession 0001628280-26-033865.Report this figure(12.2)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$12.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001628280-26-055494. Derived: 6-month figure less the 3-month figure.Capital expenditure: $185.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-11, accession 0001628280-26-055494. Derived: 6-month figure less the 3-month figure.Report this figure(31.6)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$31.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001628280-25-049854. Derived: 9-month figure less the 6-month figure.Capital expenditure: $411.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001628280-25-049854. Derived: 9-month figure less the 6-month figure.Report this figure(22.2)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$22.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012000. Derived: 12-month figure less the 9-month figure.Capital expenditure: $11.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-012000. Derived: 12-month figure less the 9-month figure.Report this figure(30.0)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$29.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001628280-26-033865.Capital expenditure: $64.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-12, accession 0001628280-26-033865.Report this figure(1.6)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$1.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001628280-26-055494. Derived: 6-month figure less the 3-month figure.Capital expenditure: $37.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-11, accession 0001628280-26-055494. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$35.9mOperating margin −320.5%
Diluted EPS−$1.27, FY2025
Free cash flow−$99.3m, FY2025
C4 Therapeutics, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m45.8Revenue, FY2021, twelve months to 2021-12-31$45.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-02-23, accession 0001628280-23-004711.Report this figure31.1Revenue, FY2022, twelve months to 2022-12-31$31.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-22, accession 0001628280-24-006144.Report this figure20.8Revenue, FY2023, twelve months to 2023-12-31$20.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-27, accession 0001628280-25-008433.Report this figure35.6Revenue, FY2024, twelve months to 2024-12-31$35.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012000.Report this figure35.9Revenue, FY2025, twelve months to 2025-12-31$35.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012000.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(179.4%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$82.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-02-23, accession 0001628280-23-004711.Revenue: $45.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-02-23, accession 0001628280-23-004711.Report this figure(416.6%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$129.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-22, accession 0001628280-24-006144.Revenue: $31.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-22, accession 0001628280-24-006144.Report this figure(669.8%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$139.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-27, accession 0001628280-25-008433.Revenue: $20.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-27, accession 0001628280-25-008433.Report this figure(336.1%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$119.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012000.Revenue: $35.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012000.Report this figure(320.5%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$115.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012000.Revenue: $35.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012000.Report this figure
Net margin%(183.2%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$83.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-02-23, accession 0001628280-23-004711.Revenue: $45.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-02-23, accession 0001628280-23-004711.Report this figure(412.2%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$128.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-22, accession 0001628280-24-006144.Revenue: $31.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-22, accession 0001628280-24-006144.Report this figure(638.3%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$132.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-27, accession 0001628280-25-008433.Revenue: $20.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-27, accession 0001628280-25-008433.Report this figure(296.0%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$105.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012000.Revenue: $35.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012000.Report this figure(292.1%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$105.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-012000.Revenue: $35.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-012000.Report this figure
Diluted EPS$ per share(1.82)Diluted EPS, FY2021, twelve months to 2021-12-31−$1.82 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-02-23, accession 0001628280-23-004711.Report this figure(2.62)Diluted EPS, FY2022, twelve months to 2022-12-31−$2.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-22, accession 0001628280-24-006144.Report this figure(2.67)Diluted EPS, FY2023, twelve months to 2023-12-31−$2.67 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-27, accession 0001628280-25-008433.Report this figure(1.52)Diluted EPS, FY2024, twelve months to 2024-12-31−$1.52 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001628280-26-012000.Report this figure(1.27)Diluted EPS, FY2025, twelve months to 2025-12-31−$1.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001628280-26-012000.Report this figure
Free cash flow$m(88.2)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$87.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-02-23, accession 0001628280-23-004711.Capital expenditure: $1.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-02-23, accession 0001628280-23-004711.Report this figure(111)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$105.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-22, accession 0001628280-24-006144.Capital expenditure: $5.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-22, accession 0001628280-24-006144.Report this figure(109)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$106.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-27, accession 0001628280-25-008433.Capital expenditure: $1.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-27, accession 0001628280-25-008433.Report this figure(65.3)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$65.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012000.Capital expenditure: $180.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-012000.Report this figure(99.3)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$98.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-012000.Capital expenditure: $607.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-012000.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding C4 Therapeutics, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
MORGAN STANLEY2026-06-30$41.4m8,867,338Reduced−205,062
RA CAPITAL MANAGEMENT, L.P.2026-06-30$37.4m8,000,000Unchanged
BlackRock, Inc.2026-06-30$36.9m7,896,718Added+5,848,192
Lynx1 Capital Management LP2026-06-30$34.2m7,326,691Added+327,789
Squadron Capital Management LLC2026-06-30$33.6m7,200,000Added+4,950,000
Bain Capital Life Sciences Investors, LLC2026-06-30$33.5m7,171,910Unchanged
JPMORGAN CHASE & CO2026-06-30$20.7m4,747,424Added+1,524,370
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$20.6m4,417,731Added+555,879
CITADEL ADVISORS LLC2026-06-30$19.6m4,187,580Added+1,676,565
GOLDMAN SACHS GROUP INC2026-06-30$16.5m3,530,991Added+1,143,613

Recent filings

All 536 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

C4 Therapeutics, Inc., recent filings
FiledFormWhat it isAccession number
2026-09-2511:04 ET8-K7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001628280-26-063497
2026-08-1111:29 ET10-QQuarterly reportPeriod 2026-06-300001628280-26-055494
2026-08-1111:14 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001628280-26-055490
2026-06-2420:22 ET8-K5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001628280-26-045194
2026-06-1111:04 ET8-K7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001628280-26-042365
2026-05-1520:03 ET8-K5.02 Departure or appointment of officers or directors0001628280-26-035542
2026-05-1211:07 ET10-QQuarterly reportPeriod 2026-03-310001628280-26-033865
2026-05-1211:05 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001628280-26-033861
2026-04-2911:00 ETDEF 14AProxy statementPeriod 2026-04-290001628280-26-028104
2026-04-1011:17 ET8-K5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits0001628280-26-024583

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 26, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1662579
Tickers
CCCC
Exchange
Nasdaq
SIC code
2836 Biological Products, (No Diagnostic Substances)
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Non-accelerated filer<br>Smaller reporting company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. Listed shows no prices and gives no investment advice.